确保抗生素研发、公平可及与合理使用:多部门行动建议
抗生素耐药是全球公共卫生威胁,WHO全球行动计划建议多部门参与。本文基于对12名第三方利益相关者的探索性定性访谈,识别抗生素研发、公平可及与合理使用的障碍,并提出消除这些障碍的建议及近期进展示例,以指导未来抗生素政策与多部门行动。
要点
- 第三方利益相关者包括政府、监管机构、抗生素研发与医学伦理专业人员。
- 障碍经对12名第三方利益相关者的探索性定性访谈识别。
- 建议用于指导未来抗生素政策与多部门政策行动。
核心结论
- 需多部门行动消除抗生素研发、公平可及与合理使用的障碍,建议可指导未来政策。
研究设计与样本
- 观点类文章,障碍基于对12名第三方利益相关者的探索性定性访谈研究识别。
主要发现
- 识别了抗生素研发、公平可及与合理使用方面的障碍,并给出消除建议及近期进展示例。
临床怎么用
- 建议可指导未来抗生素政策制定与多部门政策行动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibiotic resistance is a growing threat to global public health. The World Health Organization's Global Action Plan on Antimicrobial Resistance recommends engaging multisectoral stakeholders to tackle the issue. However, so far, few studies have addressed barriers to antibiotic development, equitable availability, and responsible antibiotic use from the perspective of stakeholders outside healthcare facilities or patient communities: the so-called third-party stakeholders. Third-party stakeholders include, inter alia, governments, regulatory agencies, and professionals working in antibiotic research and development and medical ethics. This viewpoint provides an overview of barriers to antibiotic development, equitable availability of effective antibiotics, and the responsible use of antibiotics. The barriers were identified in an exploratory, qualitative interview study with an illustrative sample of 12 third-party stakeholders. Recommendations to lift these barriers are presented, together with examples of recently-made progress. The recommendations should guide future antibiotic policies and multisectoral policy action.
引用
- Monnier AA, Schouten J, Tebano G, et al. Ensuring Antibiotic Development, Equitable Availability, and Responsible Use of Effective Antibiotics: Recommendations for Multisectoral Action. Clin Infect Dis. 2019. PMID: 30256927. doi:10.1093/cid/ciy824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。